Successful treatment with moxifloxacin of experimental aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus (MRSA)

Galani, Lambrini; Pefanis, Angelos; Sakka, Vissaria; Iliopoulos, Dimitrios; Donta, Ismini; Triantafyllidi, Helen; Skiadas, Ioannis; Karayiannakos, Panayiotis; Giamarellou, Helen

doi:10.1016/j.ijantimicag.2008.07.021

Cited by 5 publications

(4 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In vitro experiments showed that 95% of culture-negative vegetations have been achieved in oral MOX treatment [9], and all parenteral MOX groups had sterile vegetations at the end of treatment plan. e cure rate was 100%, and no relapses of IE occurred after 5 days of therapy [8]. Strains of methicillinresistant S. aureus were not resistant to MOX.…”

Section: Discussionmentioning

confidence: 89%

“…In vivo experimental analysis of MOX activity against S. Aureus shows that, with standard oral doses, MOX is both inhibitory and bactericidal against strains of S. Aureus [7]. In animal models, it is equally effective as vancomycin in the treatment of experimental aortic valve IE due to methicillin-resistant S. aureus [8]. In vitro experiments showed that 95% of culture-negative vegetations have been achieved in oral MOX treatment [9], and all parenteral MOX groups had sterile vegetations at the end of treatment plan.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Moxifloxacin Monotherapy in Left-Sided Staphylococcus aureus Endocarditis

Çölkesen¹

2021

Case Reports in Infectious Diseases

View full text Add to dashboard Cite

Staphylococcus aureus is the major cause of endocarditis, and its mortality has remained high despite therapeutic procedures over time. A case of left-sided native valve endocarditis caused by methicillin-sensitive Staphylococcus aureus which responded well to moxifloxacin monotherapy is described. An 83-year-old woman with a history of current hospitalization presented with fatigue and fever. Transthoracic echocardiography depicted vegetation, and blood cultures were positive for Staphylococcus aureus. After a 14-day intravenous administration of moxifloxacin, a good clinical response was achieved, and antibiotic regimen transitioned to oral moxifloxacin for an additional four-week therapy.

show abstract

Section: Discussionmentioning

confidence: 89%

Section: Discussionmentioning

confidence: 99%

Moxifloxacin Monotherapy in Left-Sided Staphylococcus aureus Endocarditis

Çölkesen¹

2021

Case Reports in Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…Newer fluoroquinolones such as levofloxacin and moxifloxacin also have favourable pharmacologic profile when given orally and are bactericidal against S. aureus, and in contrast to ciprofloxacin, the development of in-vivo resistance appears rare [27,33,34]. Both levofloxacin and moxifloxacin have also proved effective in animal models of infective endocarditis [35,36] and in anecdotal human cases [37,38]. Therefore, it would also be reasonable to consider the oral formulations of these drugs in future studies for the treatment of this infection.…”

Section: Discussionmentioning

confidence: 99%

Oral antibiotic therapy for the treatment of infective endocarditis: a systematic review

et al. 2014

View full text Add to dashboard Cite

BackgroundThe role of oral antibiotic therapy in treating infective endocarditis (IE) is not well established.MethodsWe searched MEDLINE, EMBASE and Scopus for studies in which oral antibiotic therapy was used for the treatment of IE.ResultsSeven observational studies evaluating the use oral beta-lactams (five), oral ciprofloxacin in combination with rifampin (one), and linezolid (one) for the treatment of IE caused by susceptible bacteria reported cure rates between 77% and 100%. Two other observational studies using aureomycin or sulfonamide, however, had failure rates >75%. One clinical trial comparing oral amoxicillin versus intravenous ceftriaxone for streptococcal IE reported 100% cure in both arms but its reporting had serious methodological limitations. One small clinical trial (n = 85) comparing oral ciprofloxacin and rifampin versus conventional intravenous antibiotic therapy for uncomplicated right-sided S. aureus IE in intravenous drug users (IVDUs) reported cure rates of 89% and 90% in each arm, respectively (P =0.9); however, drug toxicities were more common in the latter group (62% versus 3%; P <0.01). Major limitations of this trial were lack of allocation concealment and blinding at the delivery of the study drug(s) and assessment of outcomes.ConclusionReported cure rates for IE treated with oral antibiotic regimens vary widely. The use of oral ciprofloxacin in combination with rifampin for uncomplicated right-sided S. aureus IE in IVDUs is supported by one small clinical trial of relatively good quality and could be considered when conventional IV antibiotic therapy is not possible.

show abstract

“…Τα αποτελέσµατα, σε γενικές γραµµές ήταν ιδιαιτέρως ικανοποιητικά, ενώ, επιπλέον, έχουν µελετηθεί και οι φαρµακοκινητικές παράµετροι που προσδιορίζουν την επιτυχή ή µη κατάληξη της θεραπείας ανάλογα µε το µελετούµενο µικροοργανισµό[172]. Σε ένα πειραµατικό µοντέλο ενδοκαρδίτιδας αορτικής βαλβίδας από MRSA σε κονίκλους[178], η µοξιφλοξασίνη χορηγούµενη σε δόση 20 mg/kg iv, 2 φορές την ηµέρα για 4 ηµέρες, ήταν εξίσου αποτελεσµατική µε τη βανκοµυκίνη, αν και in vitro τα δύο αντιβιοτικά είχαν βακτηριοστατική δράση σε συγκεντρώσεις ίσες µε την MIC. Αξιοσηµείωτο, ήταν ότι η χορήγηση µοξιφλοξασίνης για 5 ηµέρες θεράπευσε 100% τα πειραµατόζωα, χωρίς καµία υποτροπή 5 ηµέρες µετά το ττέλος της αντιµικροβιακής θεραπείας.…”

unclassified

Χημειοπροφύλαξη με μοξιφλοξασίνη σε πειραματική ενδοκαρδίτιδα αορτικής βαλβίδας από streptococcus oralis

Σακκά¹,

Sakka²

View full text Add to dashboard Cite

χρήστες ενδοφλέβιων απαγορευµένων ουσιών Α5. ΠΑΘΟΓΟΝΟΙ ΜΙΚΡΟΟΡΓΑΝΙΣΜΟΙ Α5.1. Πρασινίζοντες στρεπτόκοκκοι Α6. ΠΑΘΟΓΕΝΕΙΑ Β. ΠΡΟΛΗΨΗ ΛΟΙΜΩ∆ΟΥΣ ΕΝ∆ΟΚΑΡ∆ΙΤΙ∆ΑΣ Β1. ΥΠΟΚΕΙΜΕΝΕΣ ΚΑΡ∆ΙΑΚΕΣ ΝΟΣΟΙ ΠΟΥ ΠΡΟ∆ΙΑΘΕΤΟΥΝ ΓΙΑ ΛΕ B1.1. Καρδιακές παθήσεις σχετιζόµενες µε αυξηµένο κίνδυνο ανάπτυξης ΛΕ Β1.2. Καρδιακές παθήσεις που σχετίζονται µε µεγαλύτερο κίνδυνο κακής πρόγνωσης ΛΕ Β2. ΙΑΤΡΟΓΕΝΗΣ ΚΑΙ ΜΗ ΙΑΤΡΟΓΕΝΗΣ ΜΙΚΡΟΒΙΑΙΜΙΑ Β.2.1. Μικροβιαιµία µετά από οδοντιατρικούς χειρισµούς και «καθηµερινές» οδοντικές συνήθειες Β.2.2. Μικροβιαιµία µετά από επεµβάσεις στην αναπνευστική οδό, το γαστρεντερικό σωλήνα και το ουροποιογεννητικό σύστηµα Β.3. ΕΚΤΙΜΗΣΗ ΤΗΣ ΑΠΟΤΕΛΕΣΜΑΤΙΚΟΤΗΤΑΣ ΤΗΣ ΧΗΜΕΙΟΠΡΟΦΥΛΑΞΗΣ ΣΤΗ ΛΟΙΜΩ∆Η ΕΝ∆ΟΚΑΡ∆ΙΤΙ∆Α Β.3.1. Μελέτες προφύλαξης σε πειραµατικά µοντέλα ενδοκαρδίτιδας σε ζωικά πρότυπα Β.3.2. Κλινικές µελέτες σχετικά µε προφύλαξη πριν από οδοντιατρικούς χειρισµούς Β.3.3. Κίνδυνος Ανεπιθύµητων Ενεργειών και Ανάλυση Κόστους-Αποτελεσµατικότητας Β.3.4. Συµµόρφωση των επαγγελµατιών υγείας και των ασθενών Β.4. ΠΡΟΤΕΙΝΟΜΕΝΑ ΣΧΗΜΑΤΑ ΧΗΜΕΙΟΠΡΟΦΥΛΑΞΗΣ ΓΙΑ ΤΗΝ ΠΡΟΛΗΨΗ ΤΗΣ ΛΟΙΜΩ∆ΟΥΣ ΕΝ∆ΟΚΑΡ∆ΙΤΙ∆ΑΣ Β.4.1. Σχήµατα χηµειοπροφύλαξης σε οδοντιατρικές επεµβάσεις. Β 4.2. Σχήµατα χηµειοπροφύλαξης σε επεµβάσεις σε αναπνευστικό, γαστρεντερικό, ουροποιογεννητικό σύστηµα Β.4.3. Ιδιαίτερες καταστάσεις και συνθήκες viii

show abstract

Successful treatment with moxifloxacin of experimental aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus (MRSA)

Cited by 5 publications

References 28 publications

Moxifloxacin Monotherapy in Left-Sided Staphylococcus aureus Endocarditis

Moxifloxacin Monotherapy in Left-Sided Staphylococcus aureus Endocarditis

Oral antibiotic therapy for the treatment of infective endocarditis: a systematic review

Χημειοπροφύλαξη με μοξιφλοξασίνη σε πειραματική ενδοκαρδίτιδα αορτικής βαλβίδας από streptococcus oralis

Contact Info

Product

Resources

About